The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.n

ILD with a granulomatous component

Publications

Bhamra K, Stevens R

Pulmonary Sarcoidosis following Etanercept Treatment.

Case reports in rheumatology 2012;2012;724013 — 2012 — 724013

Massara A, Cavazzini L, La Corte R, Trotta F

Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review.

Seminars in arthritis and rheumatism 2010 Feb;39;313-9 — 2010 Feb — 313-9

Yousem SA, Dacic S

Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005 May;18;651-5 — 2005 May — 651-5

Vavricka SR, Wettstein T, Speich R, Gaspert A, Bachli EB

Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy.

Thorax 2003 Mar;58;278-9 — 2003 Mar — 278-9